Incyte announced that the European Medicines Agency, or EMA, Committee for Medicinal Products for Human Use, or CHMP, has issued an recommending the approval of ruxolitinib cream for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on INCY:
